linjc16/ctgov huggingface dataset:
Knowledge- Attitude- Practice (KAP) of Post Exposure Prophylaxis for Fifth Year Dental Students of a Private Egyptian University

Study Overview
=================
Brief Summary
-----------------
considering the increase number of occupational injuries, The aim of this study is to assess the current level of knowledge, attitude and practice of fifth year dental students as regards post exposure prophylaxis.

Detailed Description
-----------------
Injuries from occupational accidents are associated with agents of biological risk, as they are the gateway to serious and potentially lethal infectious diseases. Several studies have demonstrated that dental students are among the most vulnerable to blood-borne exposure due to both their limited and restricted working area and developing skills level. This situation makes the use of post exposure prophylaxis is very important. Therefore, this study is conducting to evaluate the awareness level of fifth year dental students regarding post exposure prophylaxis.

Official Title
-----------------
Knowledge- Attitude- Practice (KAP) of Post Exposure Prophylaxis for Fifth Year Dental Students of a Private Egyptian University: A Cross-sectional Study

Conditions
-----------------
Occupational Exposure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria The fifth year dental students studying at a Private Egyptian University. Dental students who agree to participate. Dental students irrespective of age and sex. Exclusion Criteria: • Refusal of participation from the students.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knowledge, attitude and practice (KAP) of fifth year dental students regarding Post Exposure Prophylaxis. | the questionnaire will be given to students to be filled in one of their clinical sections | one day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
knowledge attitude practice questionnaire post exposure prophylaxis
Role of Fexofenadine in Diabetic Kidney Disease

Study Overview
=================
Brief Summary
-----------------
This study will that will be conducted on 60 outpatients previously diagnosed with type 2 diabetes mellitus. Patients will be recruited from Internal Medicine Department, Tanta University Hospital, Tanta, Egypt. This study will be randomized, controlled, parallel, prospective clinical study. Accepted patients will be randomized into 2 groups as the following Group 1 (Control group): 30 patients will receive maximum tolerated dose of ACEI for six months Group 2 (Fexofenadine group): 30 patients will receive maximum tolerated dose of ACEI plus fexofenadine tablets 60 mg once daily for six months The primary end point will be the change in Urinary albumin to creatinine ratio (UACR) after six months of treatment

Official Title
-----------------
Role of Fexofenadine in Reducing Albuminurea in Patients With Diabetic Kidney Disease

Conditions
-----------------
Diabetic Kidney Disease

Intervention / Treatment
-----------------
* Drug: Fexofenadine Pill
* Drug: Placebo oral tablet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males or females aged ≥ 18 years Confirmed diagnosis of Type 2 diabetes mellitus at least 6 months prior to screening Stage 2 and 3 diabetic nephropathy (persistent micro- or macroalbuminuria with urinary albumin creatinine ratio (UACR) >30mg/g) despite treatment with maximum tolerated dose of ACE inhibitors for at least 8 weeks prior to the screening Hemoglobin A1c > 6.5 % with regular use of insulin and/or oral glucose lowering agents Exclusion Criteria: Type 1 diabetes mellitus Severe renal impairment (eGFR< 30 mL/min/1.73 m2 at screening) Pregnant or lactating women Chronic heart failure Malignancy Inflammatory or autoimmune disease History of kidney disease other than diabetic nephropathy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Control group<br> | Drug: Placebo oral tablet<br>* lactose oral tablet<br>|
| Active Comparator: Fexofenadine group<br> | Drug: Fexofenadine Pill<br>* fexofenadine tablets 60 mg once daily will be taken for six months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent change in urinary albumin creatinine ratio (UACR) |  | After 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Urinary cyclophilin A |  | After 6 months | 
| Urinary monocyte chemoattractant protein-1 (MCP-1) |  | After 6 months |
Effect of Concomitant Bladder Neck Incision and Urethral Valve Ablation on Surgical Re-intervention Rate for Patients With Posterior Urethral Valve

Study Overview
=================
Brief Summary
-----------------
To determine the short-term effects of concurrent valve ablation and bladder neck incision on re-intervention rate for patients with posterior urethral valve.

Official Title
-----------------
Effect of Concomitant Bladder Neck Incision and Urethral Valve Ablation on Surgical Re-intervention Rate for Patients With Posterior Urethral Valve : A Randomized Controlled Trial

Conditions
-----------------
Pediatric Disorder, Hydronephrosis in Children, Hydronephrosis, Secondary, Hydronephrosis Congenital, Bladder-Neck; Obstruction, Congenital, Urethral Valve, Renal Function Disorder

Intervention / Treatment
-----------------
* Procedure: Valve ablation
* Procedure: Valve ablation and bladder neck incision


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are less than 12 years of age with presenting to the Mansoura University Urology and Nephrology Center with the diagnosis of PUV will be s creended for eligibility Exclusion Criteria: Patients with other conditions that can potentially affect lower and upper urinary tract functions Patients who were treated with urinary diversion as vesicostomy or cutaneous ureterostomy. Patients who had primary treatment of posterior urethral valve ablation at other hospitals.

Ages Eligible for Study
-----------------
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Valve ablation<br>Valve ablation | Procedure: Valve ablation<br>* Valve ablation<br>|
| Active Comparator: Valve ablation and bladder neck incision<br>Valve ablation and bladder neck incision | Procedure: Valve ablation and bladder neck incision<br>* Valve ablation and bladder neck incision<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| compare numbers of reintervention between groups | assessed by calculating the number of patients needed surgical reintervention per total number of patients in both groups | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PUV, BNI, Urethral valve, Valve ablation, Bladder dysfunction
Evaluation of a Venous-Return Assist Device (Venowave) to Treat Post-Thrombotic Syndrome: A Randomized Controlled Trial

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether daily use of a lower limb venous-return assist device, Venowave', improves leg symptoms, ability to perform activities of daily living, and quality of life in subjects with severe PTS.

Detailed Description
-----------------
Eligible consenting patients will be randomly allocated to receive either the veno-device (active or placebo for 8 weeks and crossed over for a further 8 weeks (active or placebo) following a 4 week 'wash out' period.( A randomized controlled 'crossover' study}

Official Title
-----------------
Evaluation of a Venous-Return Assist Device (Venowave) to Treat Post-Thrombotic Syndrome: A Randomized Controlled Trial

Conditions
-----------------
Postphlebitic Syndrome

Intervention / Treatment
-----------------
* Device: Veno-device (Venowave)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Past History of objectively documented deep vein thrombosis Daily leg swelling with discomfort (i.e. report at least one of the following symptoms: heavy legs, aching legs and/or throbbing) for a minimum of 6 months Over 18 years of age (and of either gender). Villalta score of greater than 14(i.e.severe post phlebitic syndrome) Exclusion Criteria: Episode of objectively documented deep vein thrombosis occurred less than 6 months before recruitment Subjects report that their symptoms have been unstable (worsening, improving or variable over the previous month). Active venous ulceration Baseline leg circumference greater than 50 cm (cuff will not fit subject) Symptomatic peripheral arterial disease Peripheral neuropathy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Veno-device (Venowave)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical Success measured with the Global Rating Instrument |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PTS-CCS questionnaire |  |  | 
| Villalta Scale |  |  | 
| Veines Quality of Life Questionnaire |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PTS, Post phlebitic Syndrome, Activities of Daily Living, Quality of Life
Dynamic Splinting After Total Knee Arthroplasty

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effectiveness of a dynamic splinting system for knee flexion contracture following a total knee arthroplasty.

Detailed Description
-----------------
The purpose of the study is to evaluate the efficacy of dynamic splinting for knee flexion contracture following a total knee arthroplasty.

Official Title
-----------------
Dynamic Splinting After Total Knee Arthroplasty: a Randomized, Controlled Trial

Conditions
-----------------
Reduced Knee Flexion

Intervention / Treatment
-----------------
* Device: Knee Extension Dynasplint


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Reduced flexibility in AROM of knee extension Pain that is worsened by bending over while legs are straight Impaired gait pattern Ability to understand informed consent and experiment responsibilities Exclusion Criteria: Fractures Knee sepsis Osteomyelitis or any orthopedic infection Extensor mechanism dysfunction Psoriasis Knee joint neuropathy Previous Stroke or Brain Injury

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: 1<br>Patient will receive post-surgical standard of care treatment with standard Physical therapy and NSAIDs. | |
| Experimental: 2<br>Patients will be treated with the Standard of Care physical therapy and NSAIDs as well as a Knee Extension Dynasplint that includes tension chambers. | Device: Knee Extension Dynasplint<br>* Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Maximal Acitive Range of Mothion in knee extension |  | 9 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
total knee arthroplasty, Dynamic Splinting, Knee extension, knee, Reduced knee flexion after total knee arthroscopy
Psycho-social Aspects After a Physiotherapy Intervention in Chronic TMD Pain

Study Overview
=================
Brief Summary
-----------------
How patients psycho-social factors change after a physical intervention in patients with chronic TMD pain

Official Title
-----------------
Psycho-social Aspects After a Physiotherapy Intervention in Chronic TMD Pain

Conditions
-----------------
TMD

Intervention / Treatment
-----------------
* Other: physiotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic myofascial TMD pain Exclusion Criteria: Neurologic pain

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: physiotherapy|manual therapy and sef-care exercises|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TSK-11 | Tampa Scale for Kinesiophobia | immediately after treatment | 
| TSK-11 | Tampa Scale for Kinesiophobia | at 3 months |
Oral Tranexamic Acid Versus Diosmin for Treatment of Menorrhagia in Women Using Copper IUD

Study Overview
=================
Brief Summary
-----------------
To compare the efficacy of tranexamic acid and diosmin in reducing menstrual blood loss in women having Intra Uterine Contraceptive Device (IUD) and suffer from menorrhagia.

Official Title
-----------------
Oral Tranexamic Acid Versus Diosmin for Treatment of Menorrhagia in Women Using Copper IUD: Randomized Controlled Trial

Conditions
-----------------
Menorrhagia

Intervention / Treatment
-----------------
* Drug: Tranexamic Acid
* Drug: Diosmin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women complaining from an menorrhagia secondary to a current copper IUD use. Age: 20-40years. Menorrhagia , will be defined as a PBAC-Score greater than 100. No systemic causes of abnormal uterine bleeding as hypertension and hemorrhagic blood diseases. No other local causes of abnormal uterine bleeding as, (fibroid, adenomyosis, polyps). No drugs decreasing blood coagulation. Well fitted IUD not misplaced. Exclusion Criteria: Age <20y and >40y. Irregular menstrual cycle. Presence of systemic causes of abnormal uterine bleeding as hypertension and hemorrhagic blood diseases. Presence of other local causes of abnormal uterine bleeding as, (fibroid, adenomyosis, polyps). Taking drugs decrease blood coagulation. Misplaced IUD.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Tranexamic acid<br> | Drug: Tranexamic Acid<br>* use tranexamic acid oral tablets 500 mg two tablets every six hour with the onset of the first day of menstrual cycle till the end of bleeding then The amount of menstrual flow will be calculated by the PBAC<br>* Other names: kapron;|
| Active Comparator: Diosmin<br> | Drug: Diosmin<br>* use diosmin oral tablets 500 mg t.d.s (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.then The amount of menstrual flow will be calculated by the PBAC<br>* Other names: dycinon;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The amount of reducing heavy menstrual flow will be calculated by the PBAC. | measure the bleeding rate will be by the pictorial blood assessment chart (PBAC). | the first 24hours |
Cognitive Behavioural Therapy of Early Dementia

Study Overview
=================
Brief Summary
-----------------
A randomized, controlled, parallel-group trial to evaluate the efficacy of a cognitive behavioral therapy for patients with early dementia.

Detailed Description
-----------------
The KORDIAL study is a randomized, controlled, parallel-group trial evaluating the efficacy of a cognitive behavioral therapy for patients at the early stage of Alzheimer's disease. The 3-month experimental intervention consists of 12 individual sessions with regular involvement of carers or other patient proxies. Strategies for improving the patient's coping ability and for enhancing their psychological well-being are combined. The primary outcome criterion is functioning in the everyday context after completion of the intervention and after another 6 months. The control condition will be treatment as usual. The study will be conducted in 5 university outpatient units and in 5 specialist offices.

Official Title
-----------------
Cognitive Behavioural Resource-based Therapy of Early Dementia in the Everyday Setting

Conditions
-----------------
Dementia

Intervention / Treatment
-----------------
* Behavioral: Cognitive behavioral therapy for early Alzheimer's disease
* Other: Control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Mild dementia (MMSE > 21) in Alzheimer's disease (ICD-10), proxy available Exclusion Criteria: Acute of unstable psychiatric or physical disease, proxy unavailable Participation in another trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Intervention | Behavioral: Cognitive behavioral therapy for early Alzheimer's disease<br>* 12 weekly individual sessions, total duration 3 months, regular involvement of patient's proxy ever second session. Intervention is manualized but is flexible with regard to individual resources and needs.<br>|
| 2<br>control | Other: Control<br>* Patients and proxies who are assigned to treatment as usual<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Functional ability in the everyday context |  | Baseline, post treatment, 6 months post treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life, depression, neuro-psychiatric symptoms |  | Same as for primary outcome | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Early dementia in Alzheimer's disease (MMSE ≥ 21)
Neuro-Orthopedic Registry of the University Hospital of Toulouse

Study Overview
=================
Brief Summary
-----------------
Neuro-orthopedics corresponds to the evaluation and therapeutic management of the orthopedic consequences of damage to the central or peripheral nervous system. In case of neurological impairment, there may be joint, motor, sensory and cognitive impairments that limit the patient's activities. The management of these orthopedic problems falls within the specific framework of neuro-orthopedics because in the presence of neurological, problems are different and more complex than in classical orthopedics. In this context, a well-conducted evaluation is a prerequisite for appropriate treatment.

Official Title
-----------------
Neuro-Orthopedic Registry of the University Hospital of Toulouse

Conditions
-----------------
Neurologic Disorder

Intervention / Treatment
-----------------
* Other: Data collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with a neurological condition that benefits: An injection of botulinum toxin in the context of spasticity : about 20 / week Pre or post-therapeutic clinical evaluation (botulinum toxin or surgery): approximately 10 / week Clinical or instrumental evaluation of the walking or upper limb (Physiological Functional Explorations): about 10 / week A medical and surgical multidisciplinary consultation about spasticity : about 15 / month A discussion during neuroorthopedic multidisciplinary consultation meeting about the patient's file and anomalies of walking: about 8 / month Implementation of a Baclofen pump (Neurosurgery): about 2 / month Functional surgery of the upper or lower limb (locomotor institute, orthopedic surgery and traumatology): about 4 / sem Exclusion Criteria: Patient (or the legal representative) who opposes the data collection.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients group<br>Patients follow-up in hospital will have data collection | Other: Data collection<br>* data collection about symptoms without any specific clinical or biological intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neurologic symptoms | Data collection | Each year until five years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neuro-Orthopedics, Register